Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients
News
Cevostamab (BFCR4350A), a bispecific antibody developed by Roche, induces durable and deep responses in heavily pre-treated patients with relapsed or refractory multiple myeloma, according to early data from a ... Read more